Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Examining a Novel FDA-approved Therapy in Desmoid Tumors
FDA approval of Nirogacistat for desmoid tumors highlights improved survival rates, quality of life, and manageable side effects for patients.
EP: 1.Key Background Information on Desmoid Tumors
EP: 2.Exploring the Heterogeneous Nature of Desmoid Tumors
EP: 3.The Role of Molecular Biomarkers in Diagnosing Desmoid Tumors
EP: 4.The Burden and Unmet Needs Associated with Desmoid Tumors
EP: 5.When to Observe Desmoid Tumors
EP: 6.Surgery, Cryotherapy, and Radiotherapy for Desmoid Tumors
EP: 7.Novel Pharmacotherapies and NCCN Guideline Recommendations
Now Viewing
EP: 8.Examining a Novel FDA-approved Therapy in Desmoid Tumors
Panelists discuss the questions below in this video.
- What was the key data that led to the FDA approval of nirogacestat in patients with desmoid tumors? How does its mechanism of action differ from other therapies? Can you describe the data from the long-term study of nirogacestat? Why is this study valuable to clinicians? From your clinical experience, how has patient satisfaction been with nirogacestat? What has long-term data demonstrated? What was found in studies that evaluated nirogacestat in patient-reported outcomes and pain control? Ovarian toxicity was seen in the clinical trials in women treated with nirogacestat. What was the outcome in these patients and is any intervention necessary?
Related Videos
Related Content
